Results 151 to 160 of about 68,732 (285)

Priced Out of Treatment: The Exorbitant Cost of Antiparasitic Drugs in the United States. [PDF]

Open Forum Infect Dis
Alperin C, Nguyen N, Duffey M, Clark EH.
europepmc   +1 more source

florio HAEMO—A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Despite therapeutic achievements in haemophilia care, there is still the need to monitor and define personal treatment outcomes and document results to achieve the best possible care. Hence, a need for unbiased, timely and comprehensive real‐world information exists to support informed shared decision‐making regarding treatment ...
Christoph Königs, Jan Astermark, Jan Blatny, Jamie O´Hara, Allfonso Iorio, Claude Negrier, Flora Peyvandi, Katharina Steinitz, Armin J. Reininger, Santiago Bonanad   +9 more
wiley   +1 more source

Methodological challenges in Dutch HTA of non-oncological orphan drugs: a retrospective analysis and price comparison using different pricing models. [PDF]

Orphanet J Rare Dis
Walraven J, Kaveh M, Uyl-de Groot C.
europepmc   +1 more source

Making the Old New Again Through the Process of Recombinant Innovation

Journal of Product Innovation Management, EarlyView.
ABSTRACT Academic Summary Recombinant innovation—the process through which atypical and unexpected combinations of knowledge generate novel outcomes—is a critical driver of organizational distinctiveness and market transformation. While prior research has focused on firm‐ and industry‐level mechanisms, less attention has been given to multilevel ...
Vittoria Magrelli, Josip Kotlar, Alfredo De Massis, Federico Frattini, Antonio Messeni Petruzzelli   +4 more
wiley   +1 more source

Trends, lag and characteristics of rare disease drug approval in the USA and China, 1983-2022. [PDF]

Orphanet J Rare Dis
Wang S, Liu X, Zou Y, Tang Y, Zuo W, Jiang R, Shang J, Tian X, Liu Q, Xu T, Zhang B, Zhang S.   +11 more
europepmc   +1 more source

Narcolepsy and rapid eye movement sleep

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA. [PDF]

Ther Adv Respir Dis
Höger P, Ries M, Olivares Rivera A, Ersöz H, Buschulte K, Fähndrich S, Kontogianni K, Herth F, Trudzinski FC.   +8 more
europepmc   +1 more source

Lucid Dreaming: Not Just Awareness, but Agency

Journal of Sleep Research, EarlyView.
ABSTRACT During lucid dreaming (LD), dreamers are aware that they are dreaming and may be able to influence the oneiric content. There has been recent debate about the relative importance of the ability to influence the dream and having agency over the pure awareness of dreaming.
Severin Ableidinger, Luigi De Gennaro, Sergio Mota‐Rolim, Serena Scarpelli, Courtney J. Bolstad, Bjørn Bjorvatn, Colin A. Espie, Yves Dauvilliers, Maria Korman, Anne‐Marie Landtblom, Giuseppe Plazzi, Kentaro Matsui, Juliana Yordanova, Adrijana Koscec Bjelajac, Catia Reis, Frances Chung, Ilona Merikanto, Yun K. Wing, Markku Partinen, Tainá Macêdo, Michael R. Nadorff, Brigitte Holzinger   +21 more
wiley   +1 more source

Can the Development of Orphan Drugs Include Wider Patient Engagement? A Citizens' Jury to Explore a Promissory Notion. [PDF]

Health Expect
Frost J, Widening Engagement Patient Advisory Group, Mandizha J, van den Dungen C, Asare L, Pope C.   +5 more
europepmc   +1 more source

Drug price setting and regulation in France [PDF]

In France, drug prices have historically been regulated but approaches to setting and regulating prices have been evolving in recent years. In 2003, the prices of new outpatient drugs, which had hitherto been entirely regulated, were semi-liberalised ...
Nathalie Grandfils
core